Kelly E. Dunn

Kelly E. Dunn

Auto-generated profile, based on publicly available information

Kelly E. Dunn

Johns Hopkins University School of Medicine, Department of Psychiatry & Behavioral Sciences, Behavioral Pharmacology Research Unit, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States; Kahlert Institute for Addiction Medicine, University of Maryland School of Medicine, 655 W Baltimore St S, Baltimore, MD 21201, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
AHAndrew S. Huhn
Andrew S. Huhn
KDKelly E. Dunn
Kelly E. Dunn

3 February 2020 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
AGAlbert Garcia-Romeu
Albert Garcia-Romeu
DCDavid Cox
David Cox
KSKirsten E. Smith
Kirsten E. Smith
KDKelly E. Dunn
Kelly E. Dunn
RGRoland R. Griffiths
Roland R. Griffiths

1 September 2019 in Journal of Substance Abuse Treatment
Verified
Journal Article
Open access
HCHoward D. Chilcoat
Howard D. Chilcoat
HAHalle R. Amick
Halle R. Amick
MSMolly R. Sherwood
Molly R. Sherwood
KDKelly E. Dunn
Kelly E. Dunn
Opioid use disorder (OUD) and its consequences are a major public health concern. The partial agonist buprenorphine is a safe and effective treatment for OUD, but concerns about abuse, misuse, and diversion of buprenorphine have been raised. This narrative review examined the rates and motives for use of illicit buprenorphine in the United States. Findings from the 17 included studies suggest the majority of study participants using illicit buprenorphine do so for reasons related to misuse (to manage opioid withdrawal symptoms or achieve or maintain abstinence from other opioids). A smaller percentage of study respondents reported using buprenorphine for reasons related to abuse (to get high). There appears to be a gap between need for buprenorphine and access to adequate treatment. Attenuation of policy-related barriers and adoption of appropriate buprenorphine use by the treatment community are critical tools in the continued effort to reduce the burdens associated with OUD.

1 January 2018 in Addictive Behaviors
Verified
Journal Article
Closed access
KDKelly E. Dunn
Kelly E. Dunn
PFPatrick H. Finan
Patrick H. Finan
DTD. Andrew Tompkins
D. Andrew Tompkins
ESEric C. Strain
Eric C. Strain

1 November 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KDKelly E. Dunn
Kelly E. Dunn
AHAndrew S. Huhn
Andrew S. Huhn
CBCecilia L. Bergeria
Cecilia L. Bergeria
CGCassandra D. Gipson
Cassandra D. Gipson
EWElise M. Weerts
Elise M. Weerts
Opioid misuse and abuse is a major international public health issue. Opioid use disorder (OUD) is largely maintained by a desire to suppress aversive opioid withdrawal symptoms. Opioid withdrawal in patients seeking abstinence from illicit or prescribed opioids is often managed by provision of a μ-opioid agonist/partial agonist in combination with concomitant medications. Concomitant medications are administered based on their ability to treat specific symptoms rather than a mechanistic understanding of the opioid withdrawal syndrome; however, their use has not been statistically associated with improved treatment outcomes. Understanding the central and/or peripheral mechanisms that underlie individual withdrawal symptom expression in humans will help promote medication development for opioid withdrawal management. To support focused examination of mechanistically supported concomitant medications, this review summarizes evidence from preclinical (N = 68) and human (N = 30) studies that administered drugs acting on the dopamine, serotonin, cannabinoid, orexin/hypocretin, and glutamate systems and reported outcomes related to opioid withdrawal. These studies provide evidence that each of these systems contribute to opioid withdrawal severity. The Food and Drug Administration has approved medications acting on these respective systems for other indications and research in this area could support the repurposing of these medications to enhance opioid withdrawal treatment. These data support a focused examination of mechanistically informed concomitant medications to help reduce opioid withdrawal severity and enhance the continuum of care available for persons with OUD.

1 December 2016 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
KDKelly E. Dunn
Kelly E. Dunn
FBFrederick S. Barrett
Frederick S. Barrett
CYClaudia Yepez-Laubach
Claudia Yepez-Laubach
AMAndrew C. Meyer
Andrew C. Meyer
BHBryce J. Hruska
Bryce J. Hruska
GBGeorge E. Bigelow
George E. Bigelow